Therapeutic efficacy of recombinant interferon-alpha in polycythaemia vera

Acta Haematologica

Volumn 99, Issue 2, 1998, Pages 89-91

  Öztürk, Ahmet ^a,b   Günay, Alp ^a   Üskent, Necdet ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b Koşuyolu Hava Lojmanlari ^*  (Turkey)

Author keywords

Polycythaemia vera; Pruritus; Recombinant interferon

Indexed keywords

PARACETAMOL; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ERYTHROCYTE COUNT; FEMALE; FEVER; HUMAN; MALE; MEAN CORPUSCULAR VOLUME; MYALGIA; NEPHROTOXICITY; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

AGED; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PRURITUS; RECOMBINANT PROTEINS;

EID: 0031885554     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040817     Document Type: Article

References (16)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L: Polycythemia vera: Stem cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-919.
2. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-143.
3. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR: Long term management of polycythemia vera with hydroxyurea. Semin Hematol 1986;23:167-171.
4. Weinfeld A, Swolin B, Westin J: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Fur J Haematol 1994;52:134-139.
5. Salem HH, Van der Weyden MB, Young IF, Wiley JS: Pruritus and severe iron deficiency in polycythaemia. Br Med J 1982;285:91-92.
6. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematological remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
7. Giles FJ, Gray AG, Brozovic M, Grant ID, Machin SJ, Richards JDM, Venutas S, Singer CR, Yong KL, Davies SC, Hoffbrand AV, Mehta AB, Thomas MJG, Goldstone AH: Alpha-interferon therapy for essential thrombocythaemia. Lancet 1988;ii:70-72.
8. Barosi G, Libertato LN, Costa A, Ascari E: Cytoreductive effects of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 1989;58:271-274.
9. Taylor PC, Dolan G, Ng J-P, Paul B, Collin R, Reilly JT: Efficacy of recombinant interferon-alpha (rIFN-α) in polycythaemia vera: A study of 17 patients and an analysis of published data. Br J Haematol 1996;92:55-59.
10. Silver RT: Interferon-α2b: A new treatment for polycythemia vera. Ann Intern Med 1993;119: 1091-1092.
11. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola F, Calogero RD: Recombinant interferon α in the treatment of polycythemia vera. Blood 1991;77:2790.
12. Messora C, Bensi L, Vecchi A, Longo R, Giacobbi F, Temperani P, Bevini M, Emilia G, Sacchi S: Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 1994;86:402-404.
13. Papineschi F, Bucalossi A, Capochiani E, Benedetti E, Bramanti E, Dastoli G, Dispensa E, Benedetti E, Spremolla G: Recombinant α2a interferon and polycythaemia vera: Clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur J Haematol 1994;53:213-217.
14. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S: Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 1993;43:316-318.
15. Muller EW, de Wolf JThM, Egger R, Wijermans PW, Huijgens PJ, Halie MR, Vellenga E: Long term treatment with interferon-α2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 1995;89:313-318.
16. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5161.